Halozyme Therapeutics Inc (HALO)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 444,091 | 281,594 | 202,129 | 402,710 | 129,085 |
| Total stockholders’ equity | US$ in thousands | 363,821 | 83,808 | 169,798 | 196,953 | 151,047 |
| ROE | 122.06% | 336.00% | 119.04% | 204.47% | 85.46% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $444,091K ÷ $363,821K
= 122.06%
Halozyme Therapeutics Inc's Return on Equity (ROE) has shown significant fluctuations over the past five years, ranging from 85.46% in December 2020 to 204.47% in December 2021, then dropping to 119.04% in December 2022. The ROE surged to 336.00% by December 2023 before decreasing to 122.06% in December 2024.
The notable increase in ROE from 2020 to 2021 indicates that the company was able to generate more profit with the shareholders' equity during that period. This improved performance could be attributed to various factors such as efficient cost management, revenue growth, or better utilization of assets.
The subsequent fluctuation in ROE in the following years suggests that there may have been changes in the company's financial structure, profitability, or operational efficiency. The sharp increase in 2023 followed by a decline in 2024 may indicate a one-time event or a transient factor impacting profitability.
Overall, the varying trends in Halozyme Therapeutics Inc's ROE highlight the need for a deeper analysis to understand the factors driving these changes and to assess the company's long-term profitability and sustainability.
Peer comparison
Dec 31, 2024